Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 and AK112 with or without chemotherapy for recurrent ovarian cancer
ChiCTR2400090899Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab and ivonescimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cadonilimabivonescimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400090899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090899.